FindTrial
Sign In

Cell Infusion

BIOLOGICAL6 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Providence Health & Services, UNC Lineberger Comprehensive Cancer Center, Masonic Cancer Center, University of Minnesota

Conditions

Acquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell AplasiaColorectal CancerGraft FailureHemoglobinopathiesHodgkin LymphomaKRAS G12V Mutant Advanced Epithelial CancersKidney Cancer

Phase 1

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
Active, not recruitingNCT03354390
National Heart, Lung, and Blood Institute (NHLBI)Kidney Cancer
Start: 2018-07-20End: 2029-03-03Updated: 2026-04-28
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RecruitingNCT06090864
UNC Lineberger Comprehensive Cancer CenterHodgkin Lymphoma, Refractory, Relapse
Start: 2024-04-25End: 2031-07-01Target: 31Updated: 2025-10-20

Phase 2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RecruitingNCT06412497
Masonic Cancer Center, University of MinnesotaAcquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria +1
Start: 2024-06-05End: 2036-05-01Target: 60Updated: 2026-06-03
Allo HSCT for High Risk Hemoglobinopathies
RecruitingNCT06872333
Masonic Cancer Center, University of MinnesotaGraft Failure, Hemoglobinopathies, Sickle Cell Disease
Start: 2024-11-19End: 2032-06-01Target: 62Updated: 2026-06-04

Unknown Phase

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors
NCT05389514
Providence Health & ServicesKRAS G12V Mutant Advanced Epithelial Cancers
Updated: 2025-11-20
Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS
NCT07614048
Providence Health & ServicesColorectal Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Updated: 2026-05-29

Related Papers

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus
Journal for ImmunoTherapy of Cancer2024-08-016 citations
Abstract 3601: Improving killing of renal cell carcinoma through the combined effects of TCR engineered CD4+ and CD8+ T cells
Cancer Research2024-03-22
Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).
Journal of Clinical Oncology2024-01-298 citations
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
Journal of Clinical Oncology2023-06-015 citations
A phase I study of HERV-E TCR transduced autologous T Cells (HERV-E TCR T Cells) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)
Annals of Oncology2018-10-014 citations